ReviewToxins2018
The Role of Gut Microbiota and Diet on Uremic Retention Solutes Production in the Context of Chronic Kidney Disease.
Review in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Non-Pharmacological Interventions Aimed at Changing the Gut Microbiota for Preventing the Progression of Diabetic Kidney Disease.Nutrients · 2025Pooled it
- The gut microbiota profile of adults with kidney disease and kidney stones: a systematic review of the literature.BMC nephrology · 2020Pooled it
- Trial
- Decoding the urinary metabolome of aromatic amino acid pathways in Alport syndrome.Analytical and bioanalytical chemistry · 2026Article
- Amino acid homeostasis in the kidney: Physiological roles and pathological dysregulation.Physiological reports · 2026Review
- The effect of dietary fiber based on fermentability and viscosity on the gut microbiome composition in chronic kidney disease: a systematic review of experimental and clinical trials.Research square · 2026Article
- Microbiota-driven mechanisms in multisystem diseases: integrative evidence across cardiovascular, metabolic, neurological and autoimmune disorders.Antonie van Leeuwenhoek · 2026Review
- Pediatric and adult point of view on the gut-kidney axis in CKD.Pediatric nephrology (Berlin, Germany) · 2026Review
- Comprehensive Conservative Management as Rescue Therapy After Haemodialysis Failure: Two Case Reports.Clinics and practice · 2026Article
- Nutritional Modulation of the Gut-Kidney Axis.Nutrients · 2026Review
- A guide to uraemic toxicity.Nature reviews. Nephrology · 2026Review
- Gut microbiota-liver-kidney axis in diabetic kidney disease: mechanistic insights into amino acid metabolism and nutritional intervention strategies targeting natural bioactive compounds.Frontiers in nutrition · 2026Review
- A specifically designed multi-biotic reduces uremic toxin generation and improves kidney function.Gut microbes · 2025Article
- Article
- Intradialytic optical assessment of C-mannosyl tryptophan removal using spent dialysate.Scientific reports · 2025Article
- Individualized Diets in Patients with Kidney Disease and Kidney Transplants: A Narrative Review.Life (Basel, Switzerland) · 2025Review
- High-Diversity Plant-Based Diet and Gut Microbiome, Plasma Metabolome, and Symptoms in Adults with CKD.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- The influence of gut microbiota on the gut-brain-kidney axis and its implications for chronic kidney disease.Frontiers in microbiology · 2025Review
- Advances in kidney disease: pathogenesis and therapeutic targets.Frontiers in medicine · 2025Review
- Canagliflozin attenuates kidney injury, gut-derived toxins, and gut microbiota imbalance in high-salt diet-fed Dahl salt-sensitive rats.Renal failure · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uremic retention solutes (URS) are associated with cardiovascular complications and poor survival in chronic kidney disease. The better understanding of the origin of a certain number of these toxins enabled the development of new strategies to reduce their production. URS can be classified according to their origins (i.e., host, microbial, or exogenous). The discovery of the fundamental role that the intestinal microbiota plays in the production of many URS has reinstated nutrition at the heart of therapeutics to prevent the accumulation of URS and their deleterious effects. The intestinal microbiota is personalized and is strongly influenced by dietary habits, such as the quantity and the quality of dietary protein and fibers. Herein, this review out lines the role of intestinal microbiota on URS production and the recent discoveries on the effect of diet composition on the microbial balance in the host with a focus on the effect on URS production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.